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ABSTRACT 
An acetic acid derivative ketorolac tromethmine has found its applicability in both gram positive and gram negative bacterial ocular 
infection and used commonly associated with multiple doses. Ophthalmic medication stored in multiple dose containers is required 
by the U.S. Food and Drug Administration to contain a preservative so that patients are provided with microbe free medication. 
Benzalkonium chloride in concentrations from 0.1% to 0.0001% induced dose-dependent growth arrest and conjunctiva epithelial 
cell death, either delayed or immediately after administration. In such case, a preservative Benzalkonium chloride must be used 
within reasonable bound. Benzalkonium chloride can provide more help than harm. Hence the present study focusing on to  
formulate a formulation for ketorolac tromethmine (0.5%) ophthalmic solution using different concentration of Benzalkonium 
chloride as preservative. 
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INTRODUCTION 
Delivery of medication to the human eye is an integral 
part of medical treatment.
 
Ophthalmic drug delivery is 
one of the most interesting and challenging endeavours 
facing the pharmaceutical scientist. The anatomy, 
physiology, and biochemistry of the eye render this 
organ highly impervious to foreign substances
1
. A 
significant challenge to the formulator is to circumvent 
the protective barriers of the eye without causing 
permanent tissue damage. Development of newer, more 
sensitive diagnostic techniques and novel therapeutic 
agents continue to provide ocular delivery systems with 
high therapeutic efficacy
2
. Ophthalmic preparations are 
specialized dosage forms designed to be instilled onto 
the external surface of eye (topical), administered inside 
(intraocular), adjacent to the eye (periocular) or used in 
conjunction with any special device. The preparation 
may have any several purposes like therapeutic, 
prophylactic or palliative
3,4
. The versatility of dosage 
form enables therapeutic agent to be suitable for 
function of preparation. Therapeutically active 
formulation may be designed to provide extended action 
for either convenience or reduction in dose frequency, 
improved bioavailability of an agent or improved 
delivery to target tissue. The residence time of an ocular 
preparation may range from few seconds (ophthalmic 
solutions) to hours (gel, ointments), to months or years 
(intra ocular or periocular dosage forms). Ophthalmic 
preparations are similar to parenteral dosage form in 
their requirements for sterility as well as consideration 
for osmotic pressure (tonicity), preservation, and tissue 
compatibility, avoidance of pyrogen and particulate 
matter and suitable packaging
5,6,7
. 
This effect of NSAIDs is due to the inhibition of the 
enzyme COX, which converts arachidonic acid to 
prostaglandins, TXA2 and prostacyclin. 
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Acetylsalicylic acid irreversibly inactivates COX-1 and 
COX-2 by acetylation of a specific serine residue. Other 
NSAIDs reversibly inhibit COX-1 and COX-2 
Additional anti-inflammatory mechanism may include: 
- Interference with the potentiative action of other 
mediators of inflammation – bradykinin, histamine, 
serotonin 
- Modulation of T-cell function 
- Stabilization of lysosomal membranes 
- Inhibition of chemotaxis
8,9,10
 
Analgesic effect of NSAIDs 
This effect of NSAIDs is thought to be related to the 
peripheral inhibition of prostaglandin production, but it 
may also be due to the inhibition of pain stimuli at a 
subcortical site. 
NDAIDs prevent the potentiating action of 
prostaglandins on endogenous mediators of peripheral 
nerve stimulation (e.g. bradykinin) 
Ketorolac tromethamine is a nonsteroidal anti-
inflammatory drug which, when administered 
systemically, has demonstrated analgesic, anti-
inflammatory, and anti-pyretic activity. The mechanism 
of its action is thought to be due to its ability to inhibit 
prostaglandin biosynthesis. Ketorolac tromethamine 
given systemically does not cause pupil constriction
11
. 
Prostaglandins have been shown in many animal models 
to be mediators of certain kinds of intraocular 
inflammation. In studies performed in animal eyes, 
prostaglandins have been shown to produce disruption 
of the blood-aqueous humour barrier, vasodilation, 
increased vascular permeability, leukocytosis, and 
increased intraocular pressure
12,13
. Prostaglandins also 
appear to play a role in the mitotic response produced 
during ocular surgery by constricting the iris sphincter 
independently of cholinergic mechanisms
14,15
. 
MATERIAL AND METHODS 
Ketorolac tromethamine was received as generous gift 
from MSN Laboratories Ltd, Medak, A.P India. 
Benzalkonium chloride USP, Sodium chloride USP, 
Disodium EDTA USP, Sodium hydroxide USP, 
Hydrochloric acid USP, were received from Merck 
Chemicals Mumbai. All other chemicals used were of 
analytical reagent grade, available commercially and 
used as such without further processing.  
Methods: The excipients Benzalkonium chloride is 
used as preservative, sodium chloride as isotonic 
modifier and remaining are as diluents. 
Collect of water for injection in a cleaned glass 
container and parching it with nitrogen gas for 30 min. 
Take some of water for injection of in cleaned stainless 
steel vessels to it add and dissolve EDTA disodum, 
octoxynol40, sodium chloride under continuous stirring 
to get a clear solution. Weigh accurate batch quantity of 
Ketorolac tromethamine add and dissolve it into the 
bulk solution of under constant stirring to dissolve it 
completely. Measure accurate quantity of benzalkonium 
chloride and add and dissolve it into the bulk solution of 
step no3 to dissolve it completely. Check the pH of the 
resultant bulk solution and if necessary, adjust the pH to 
7.4 using 1N Sodium Hydroxide solution for 1N 
Hydrochloric acid solution. Make up the volume of the 
bulk solution to 1 litre using water for injection. 
Remove the resultant solution (approx) as a before 
filtration sample and submit it for analysis. Filter the 
remaining bulk solution through 0.22 µ PVDF 
membrane filter submit the after filtration sample for 
analysis. Fill the filtered bulk solution into 5ml 3 piece 
and 5ml BFS containers with fill volume of 3ml 
 
RESULT & DISCUSSION 
Table 1: Formulation of Ketorolac Ophthalmic solution 
Name of the 
Ingredients 
T1 
(mg/ml) 
T2 
(mg/ml) 
T3 
(mg/ml) 
T4 
(mg/ml) 
T5 
(mg/ml) 
T6 
(mg/ml) 
T7 
(mg/ml) 
T8 
(mg/ml) 
T9 
(mg/ml) 
Ketorolac 
tromethamine 
5 5 5 5 5 5 5 5 5 
Benzalkonium 
chloride 
0.00 0.05 0.06 0.08 0.1 0.12 0.05 0.06 0.08 
Disodium 
EDTA 
1.0 1.0 1.0 1.0 1. 1.0 1.0 1.0 1.0 
Sodium 
chloride 
7.9 7.9 7.9 7.9 7.9 7.9 6.0 6.5 7.9 
Octoxynol 40 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Hydrochloric 
acid 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
Sodium 
hydroxide 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
adjust 
pH 
Water for 
injection 
Qs QS QS QS QS QS QS QS QS 
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Procedure for preservative efficacy test: 
Take required number of product containers to collect 
15ml of product and transfer the product into the six 
sterile test tubes Label all the containers with Name of 
Sample, B. No., Name of the organism and Date 
Inoculation. Vortex the selected tube of the respective 
culture and add 0.15ml of the selected culture 
suspension of organisms to the tubes containing 15ml of 
sample each Vortex the contents 
Note:  The volume of culture suspension used should be 
in between 0.5% and 1% of the volume of the product in 
the container 
9.5Record the calculation details of quantity of culture 
suspension required for each organism in format for 
Sample preparation.  Carry out the Initial count of the 
cultures which is added to the Sample as given in 6.1.2 
to 6.1.6; 8.0 & 9.0 to a dilution up to 10
-7
 and using 9ml 
of  Sterile Dey-Engley Neutralizing broth as 
Diluent and document the colony count details in the 
Report for Initial count. At the end of 6 hours (From the 
culture addition to the product), carryout the serial 
dilution of the sample test tube as per illustration below. 
Select the container which is inoculated with Escherichia 
coli, mix the solution by using vortex mixer and transfer 
1ml to 9ml of sterile neutralizer (Dey-Engley 
Neutralizing broth) Label the tube with organism name 
and dilution (10
-1
).Vortex the tube (10
-1
) and transfer 
1ml each of dilution to a set of sterile petridish labelled 
as 10
-1
 with the name of Sample, B. No. Time interval 
and Date. and to a tube containing 9ml of sterile 
neutralizer, Label the tube with organism name and 10
-2
. 
Follow step number 13.2 for serial dilution up to tube 
labeled as10
-
6. Pour about 20ml of pre-sterilized media 
of Soyabean casein digest agar to each petriplate and 
gently rotate the plates in clockwise and anticlockwise 
direction on the LAF bench for uniform mixing of 
culture and media. Allow the plates to solidify. After 
solidification of plates, incubate all the plates at 30 to 
35
o
C for 3 days. Repeat the step 13.1 to 13.5 with, 
Pseudomonas aeruginosa, Staphylococcus aureus & 
Environment Isolate Repeat with A. niger & C. albicans 
except using Sabouraud dextrose agar and incubating at 
20°C to 25°C for 5 to 7 Days. Record the colony counts 
in the format for Report for 6 Hrs.  The inoculated 
sample containers has to be stored at 20 to 25°C up to 28 
days for further testing as per schedule time points. 
Repeat the procedure for 24 hours, 7
th
 day, 14
th
 day and 
28
th
 days & Record in the respective Time point reports. 
Calculate the log reduction after each time point of test 
as per formula in Report. Acceptance Criteria for 
Parenteral and ophthalmic preparations. 
 
Table 2: 
Microorganism Log reduction 
6 Hours 24 Hours 7 Day 14 Day 21 Day 28 Day 
Bacteria A 2 3 - - - NR* 
B - 1 3 - - NI** 
Fungi A - - 2 - - NI** 
B - - - 1 - NI** 
*  NR: No recover      **  NI: No increase 
 
The A criteria express the recommended efficacy to be 
achieved.  In justified case where the A criteria cannot 
be attained, for example for reasons of an increased risk 
of adverse reactions, the B criteria must be satisfied. 
Report the results in the Summary Report. 
Stability 
The design of the formal stability studies for the drug 
product should be based on knowledge of the behavior 
and properties of drug substance and from stability 
studies on the drug substances. The likely changes on 
storage and the rationale attributes to be tested in formal 
stability studies should be stated. 
 
Table 3: Stability Protocol 
Product Ketorolac Tromethamine Ophthalmic Solution 0.5% 
Pack: 3Piece container and 
BFS  –5mL 
Condition 
Time 
points 
Analytical parameters 
Number of 
Samples 
Description Assay  
Preservative 
Content 
Osmolality and Drop 
Size study 
pH   
40°C ± 2°C/ 
not more than 
(NMT) 25% 
RH 
INT Complies Complies Complies 7.2 00 
2 w Complies Complies Complies 7.2 08 
1 M Complies Complies Complies 7.3 08 
2 M Complies Complies Complies 7.2 08 
3 M Complies Complies Complies 7.1 08 
6 M Complies Complies Complies 7.2 08 
25°C ± 2°C/ 1 M Complies Complies Complies 7.3 08 
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40%±5%RH 3 M Complies Complies Complies 7.4 08 
6 M Complies Complies Complies Complies 7.2 08 
30°C ± 2°C/  
65 %±5%RH 
1 M Complies Complies Complies Complies 7.3 08 
3 M Complies Complies Complies Complies 7.6 08 
6 M Complies Complies Complies Complies 7.3 08 
60°C 
1 w Complies Complies Complies Complies 7.1 08 
2 w Complies Complies Complies Complies 7.2 08 
1M Complies Complies Complies Complies 7.0 08 
 
From the above stability report for six months at 
different temperature and humidity condition the 
product is found to be stable and complies according to 
the limit. 
CONCLUSION         
The designed optimized formulation T-6 with minimum 
concentration of Benzalkonium chloride will provide 
better therapeutic effect without the corneal irritation 
caused due the deposition of Benzalkonium chloride. 
The optimized formulation with minimum concentration 
of Benzalkonium chloride, will meet the compendia 
requirement of preservative efficacy test, so that it will 
maintain the sterility of the product throughout the shelf 
life of product. Formulation has effective antimicrobial 
activity without interference with the mechanism of 
action of the active ingredient. As there will no eye 
irritation and conjunctival epithelial cell death, 
optimized formulation will help to achieve the better 
patient compliance and improved therapeutics with 
reduced systemic side effects and toxicity in ocular 
bacterial infection. The selected packaging material will 
provide the better stability at both room and elevated 
conditions of temperature and humidity. No or 
minimum introduction of extractable and leachable in 
the product from the packaging material. 
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